Skip to content

Study · Non-randomized trial · n = 52 · 2024

4 results

[Neuprotection of post-acute COVID-19 cognitive impairment].

Melnik EA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2024

PMID39113450 (opens in a new tab)DOI10.17116/jnevro2024124071106 (opens in a new tab)PepBankPUB-39113450
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with post-Covid cognitive impairment, concentration improved significantly during Cortexin treatment.

    In plain wordsPatients with post-Covid cognitive impairment showed significantly better concentration during Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseConcentration
    Study

    n = 52

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    During treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (ppp=0.002).
    2 context sentences
    Summary · context
    Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed.
    Summary · context
    The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with post-Covid cognitive impairment, executive function control increased significantly during Cortexin treatment.

    In plain wordsPatients with post-Covid cognitive impairment showed better control of executive functions during Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseExecutive function control
    Study

    n = 52

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    During treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (ppp=0.002).
    2 context sentences
    Summary · context
    Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed.
    Summary · context
    The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with post-Covid cognitive impairment, auditory-verbal memory improved significantly during Cortexin treatment.

    In plain wordsPatients with post-Covid cognitive impairment showed significantly better auditory-verbal memory during Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseAuditory-verbal memory
    Study

    n = 52

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    During treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (ppp=0.002).
    2 context sentences
    Summary · context
    Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed.
    Summary · context
    The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months.
  4. 04HumanNon-randomized trialSafety outcome

    No adverse events occurred in the Cortexin group with post-Covid cognitive impairment.

    In plain wordsNo adverse events occurred in patients who received Cortexin for post-Covid cognitive impairment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableAdverse events
    Study

    n = 52

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    There were no adverse events in the MG.
    2 context sentences
    Summary · context
    Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed.
    Summary · context
    The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.